Shots:

• Equillium to receive ~$26.0M up front, ~$138.5M for option exercise & milestones from development through the first commercial sale
• Ono to get an exclusive option to purchase rights to itolizumab (mAb targeting CD6) across therapeutic indications & also obtains the rights to commercialize itolizumab in the US, Canada, Australia & New Zealand
• Equillium will be responsible to conduct the R&D of itolizumab & Ono will fund the R&D of itolizumab during the exercise period. Equillium continues to advance the therapy in the P-III (EQUATOR) study for aGvHD &(EQUALISE) study for LN & also advances the wholly-owned pipeline of multi-cytokine inhibitors through multiple milestones, incl. P-II study of EQ101 in AA & P-I study of EQ102 in CD

Ref: Globenewswire | Image: Equillium